Table 3.
Detailed information of 19 patients experienced 2009 pandemic influenza A (H1N1) with pulmonary involvement
| Patient no. | Age (years)/sex | Underlying disease/condition | Days from symptom onset to admission | Location of treatment | Chest radiographic finding(s) | Oseltamivir therapy* | Timing of starting oseltamivir therapy after onset of symptoms | Complication(s) | Blood culture | Other diagnostic test(s) for bacterial coinfection |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 11/M | None | 4 | Medical ward | Interstitial infiltrates | No | – | None | ND | ND |
| 2** | 6/F | Thalassemia | 7 | ICU | Consolidation and pleural effusion | Yes | ≥2 days | Respiratory failure; renal failure; myocarditis; intracranial hemorrhage; ARDS | Negative | Negative for Mycoplasma IgM and urine Streptococcus Pneumoniae antigen; negative bacterial and fungal culture for bronchoalveolar lavage |
| 3 | 2/M | None | 5 | Medical ward | Consolidation | Yes | ≥2 days | None | Negative | Negative for Mycoplasma IgM |
| 4 | 14/M | None | 5 | ICU | Interstitial infiltrates | Yes | ≥2 days | Seizure*** | Negative | ND |
| 5 | 4/M | None | 1 | Medical ward | Consolidation | Yes | ≥2 days | None | Negative | Negative for Mycoplasma IgM |
| 6 | 4/M | None | 1 | Medical ward | Interstitial infiltrates | Yes | <2 days | None | ND | ND |
| 7 | 8/M | None | 3 | ED | Interstitial infiltrates | Yes | ≥2 days | None | ND | ND |
| 8 | 10/F | None | 2 | Medical ward | Interstitial infiltrates | Yes | <2 days | None | ND | ND |
| 9 | 7/F | None | 1 | ED | Consolidation | Yes | <2 days | None | ND | ND |
| 10 | 12/M | Glycogenosis, status post‐liver transplant | 3 | ED | Interstitial infiltrates | Yes | ≥2 days | None | ND | ND |
| 11 | 4/F | None | 6 | ICU | Consolidation and pleural effusion | Yes | ≥2 days | ARDS | Negative | Negative for Mycoplasma IgM; negative bacterial culture and fungal for bronchoalveolar lavage and pleural effusion |
| 12 | 11/F | None | 5 | Medical ward | Consolidation | Yes | ≥2 days | None | Negative | Negative for urine Streptococcus Pneumoniae antigen |
| 13 | 1/F | None | 6 | Medical ward | Consolidation | Yes | ≥2 days | None | ND | ND |
| 14 | 8/M | None | 2 | Medical ward | Interstitial infiltrates | Yes | <2 days | None | ND | Positive throat swab for Group A Streptococcus antigen |
| 15 | 50/M | Liver cirrhosis | 3 | Medical ward | Consolidation and pleural effusion | Yes | ≥2 days | None | Negative | Negative bacterial culture for pleural effusion |
| 16 | 3/M | None | 3 | Medical ward | Interstitial infiltrates | Yes | ≥2 days | None | Negative | Negative for Mycoplasma IgM |
| 17 | 9/M | Asthma | 2 | Medical ward | Consolidation | Yes | ≥2 days | None | Negative | Positive for Mycoplasma IgM† |
| 18 | 9/M | None | 1 | ED | Consolidation | Yes | <2 days | None | ND | ND |
| 19 | 10/M | None | 2 | ED | Interstitial infiltrates | No | – | None | ND | Positive for Mycoplasma IgM† |
M, male; F, female; ICU, intensive care unit; ED, emergency department; ARDS, acute respiratory distress syndrome; ND, not done.
*Patients no. 11 and 12 received 14‐ and 10‐day oseltamivir therapy; the rest 15 patients each received a standard course of 5‐day oseltamivir therapy.
**The only case turned out to be fatal.
***The patient received treatment acyclovir because of herpes encephalitis was clinically suspected.
†The patients received treatment with azthromycin.